非酒精性脂肪肝患者血清抵抗素与胰岛素抵抗关系的研究

目的 探讨非酒精性脂肪肝患者血清抵抗素水平及其与肥胖、胰岛素抵抗、血糖、血脂的关系.方法 选择非酒精性脂肪肝患者100例,正常对照30例,采用ELISA方法测定空腹血清抵抗素,同时检测其身高、体重、腰围、臀嗣、血糖、血脂、肝功能及胰岛素水平,并计算体重指数、腰臀比和胰岛索敏感指数.结果 非酒精性脂肪肝患者血清抵抗素水平为17.68±5.2 ng.ml,高于正常对照组的12.85±4.4 ng.ml,P<0.01.相关分析显示,血清抵抗素与体重指数、甘油三酯呈正相关关系(分别为r=0.376、0.426,P<0.05),与胰岛素敏感指数呈负相关关系,(r=-0.584,P<0.01),而与腰臀比、总胆固醇、低密度酯蛋白胆固醇、高密度脂蛋白胆固醇、血糖无相关性,(P>0.05).结论 在非酒精性脂肪肝的发病过程中,抵抗素可能参与了胰岛素抵抗.     

非酒精性脂肪肝血浆抵抗素与肥胖和胰岛素抵抗关系的研究

目的探讨非酒精性脂肪肝(NAFLD)血浆抵抗素与肥胖和胰岛素抵抗的关系。方法对兰州大学第一医院2005年10月至2006年2月60例NAFLD患者和28名年龄、性别相匹配的正常对照者,采用ELISA方法测定空腹血浆抵抗素,同时检测其身高、体重、腰围、臀围、血压、血糖、血脂、肝功能及胰岛素水平,并计算体重指数、脂肪百分比、腰臀比和胰岛素抵抗指数。结果NAFLD组与正常对照组相比,其血浆抵抗素明显升高[(8.56±2.5)ng/mL对(6.39±2.81)ng/mL,P<0.01]。相关分析显示血浆抵抗素与空腹胰岛素、胰岛素抵抗指数呈显著正相关(分别为r=0.271,P=0.036;r=0.30,P=0.020);而与腰臀比、体重指数、脂肪百分比、收缩压、舒张压、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、血糖无相关性(P>0.05)。结论NAFLD患者血浆抵抗素明显升高,与胰岛素抵抗程度呈显著正相关,与肥胖无相关性。因而抵抗素可能主要与肝源性胰岛素抵抗有关,而与肥胖相关的胰岛素抵抗无关。     

非酒精性脂肪肝患者血浆抵抗素水平测定及与胰岛素抵抗的相关性

目的 探讨血浆抵抗素水平变化在非酒精性脂肪肝（NAFLD）发病中的作用及与胰岛素抵抗（IR）的关系。方法选择32例单纯NAFLD患者（F组）、29例NAFLD并2型糖尿病患者（FD组）和30例体检正常者（对照组）,分别测定空腹血浆抵抗素、空腹血糖（FPG）及胰岛素（FINS）水平,计算胰岛素敏感指数（ISI）,并分析其相关性。结果F组和FD组血浆抵抗素水平、FINS及ISI均明显高于对照组,尤以FD组为著;且血浆抵抗素水平与FINS、FPG呈正相关,与ISI呈负相关。结论NAFLD患者血浆抵抗素水平升高（尤以并2型糖尿病者为著）,并与ISI呈负相关;此可能在NAFLD等IR相关性疾病的发生、发展中具有一定作用。     

非酒精性脂肪肝与胰岛素抵抗

目的探讨非酒精性脂肪性肝病（NAFLD）与胰岛素抵抗（IR）的关系。方法NAFLD组52例,非NAFLD组50例,比较两组间BMI、WHR、TC、TG、CRP、HDL-C、LDL-C、ALT、Cr、FBG、FINS和HOMA-IR的差异,并进行Logistic回归分析。结果NAFLD组与非NAFLD组在BMI（26.7±2.3与22.4±2.5,P〈0.01）、WHR（0.94±0.06与0.83±0.05,P〈0.01）、TG（2.4±0.6与1.8±0.6,P〈0.01）、ALT（37.3±8.3与28.1±7.2,P〈0.05）、FBG（6.2±1.4与5.2±0.7,P〈0.01）、FINS（23.6±13.6与8.6±3.5,P〈0.01）、HOMA-IR（6.7±4.7与2.0±1.6,P〈0.01）的差异有统计学意义,Logistic回归分析显示BMI（P〈0.01）、WHR（P〈0.01）、TG（P〈0.01）、ALT（P〈0.05）、HOMA-IR（P〈0.01）是NAFLD的独立影响因素。结论BMI、WHR、TG、ALT、HOMA-IR是NAFLD的独立影响因素。     

非酒精性脂肪肝患者瘦素抵抗和胰岛素抵抗研究

为了研究非酒精性脂肪肝(NAFL)患者的瘦素(Leptin)抵抗和胰岛素抵抗的状况，对40例NAFL患者和30例正常对照组的血清瘦素、胰岛素等水平进行了分析研究，现将结果报道如下。     

非酒精性脂肪肝与胰岛素抵抗

鉴于在一般人群特别是肥胖人群和2型糖尿病人群中合并非酒精性脂肪肝（NAFL）者增加，NAFL的重要性已引起临床重视。本期胰岛素抵抗及其相关疾病专栏刊出了颜红梅、路影和姚定国等作者撰写的有关NAFL的文章，分别对无糖尿病、糖耐量减低（IGT）和2型糖尿病三种人群伴发NAFL和胰岛素抵抗的相关性等进行了临床观察比较。为此，特请本刊编委高鑫教授就NAFL与胰岛素抵抗的相关机制及其对2型糖尿病的防治意义发表评论，期望引起读、作者和临床同道的关注，进一步开展对NAFL的临床和相关机制的研究。[编者按]     

非酒精性脂肪肝与胰岛素抵抗

非酒精性脂肪肝(NAFLD)是指无酒精摄取史的人群发生类似酒精性脂肪肝的组织学及生化改变的临床综合征。NAFLD常与肥胖、2型糖尿病、高血压、高脂血症等代谢综合征相伴随,其共同之处在于存在胰岛素抵抗(IR)。IR是导致NAFLD发生及进展的根本原因,改善胰岛素敏感性有助于缓解或治疗NAFLD。     

非酒精性脂肪肝与胰岛素抵抗的关系

探讨非酒精性脂肪肝(NAFL)发病与胰岛素抵抗的关系。对63例受检者用放免法测定血清胰岛素,稳态模型法计算胰岛素抵抗指数。同时选择20例无脂肪肝肥胖者作为对照组。脂肪肝组与对照组比较,血清胰岛素、胰岛素抵抗指数显著性增高(P<0.001),重度脂肪肝与中度脂肪肝、轻度脂肪肝比较,血清胰岛素、胰岛素抵抗指数也存在明显增高(P<0.05)。胰岛素抵抗可能系脂肪肝发病的原发因素,而非继发性改变。     

非酒精性脂肪肝与肥胖及胰岛素抵抗的关系

探讨非酒精性脂肪肝 (NASH)的体脂含量和分布特征 ,血脂情况及与胰岛素抵抗的关系。对 87例观察对象分为NASH组 (30例 )和对照组 (5 7例 ) ,检测身高、体重、血脂、血糖、血胰岛素 ,计算胰鸟素敏感指数和体重指数 ;做腹部CT扫描以其配备软件计算腹内脂肪面积 (VA)和腹皮下脂肪面积 (SA)。 6 8例肥胖者发生NASH2 8人(41 18% ) ,19例体重正常者发生HASH2人 (10 5 3% )。 (x2 =6 175 ,P <0 0 2 5 )差异有显著性。不伴NASH的肥胖者VA(x±s,cm2 ) (男 :10 5 8± 2 9 6　女 :117 3± 33 1)与伴有NASH的肥胖者VA(男 :138 2± 5 3 7　女 :14 2 6± 31 2 )比较差异有显著性 (t =2 72 ,2 31　P <0 0 1,0 0 5 )。无NASH肥胖者与伴有NASH肥胖者比较IAI差异有显著性 (t =1 98　P <0 0 5 )。肥胖尤其是腹内型肥胖与NASH有密切的关系 ;肥胖者发生NASH ,胰岛素抵抗在其中起重要作用。     

应用胰岛素抵抗替代指标评估2型糖尿病患者非酒精性脂肪肝及进展性肝纤维化的价值

目的:探讨新诊断2型糖尿病患者胰岛素抵抗替代指标与非酒精性脂肪肝(non-alcoholic fatty liver disease, NAFLD)及进展性肝纤维化患病风险的相关性。方法:选取2018年6月至2020年6月上海交通大学医学院附属第九人民医院内分泌科住院的429例新诊断2型糖尿病患者作为研究对象,按腹部超...     

Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease

BACKGROUND/AIMS: Data from animal models of fibrosis and fatty liver suggest that leptin may mediate the profibrogenic responses in the liver, but the association of leptin and liver fibrosis in human nonalcoholic fatty liver disease (NAFLD) remains undefined. We aimed at determining the relation between leptin and liver fibrosis in human NAFLD. METHODS: Human plasma leptin and several indicators of insulin resistance were measured in 88 NAFLD patients and matched controls. RESULTS: Leptin levels were significantly greater in patients with more advanced fibrosis (P = 0.005). By multivariate analysis, the significant association between leptin and fibrosis was abolished (adjusted P = 0.3) when controlling for confounders including age, gender, BMI, diabetes and insulin resistance. Only age (adjusted P = 0.006) and insulin sensitivity (adjusted P = 0.04) correlated significantly with fibrosis stage. A second liver biopsy was performed in 39 out of the 88 patients at 27.9 +/- 16 months. Leptin levels were not significantly different between patients who had fibrosis progression (n = 10) and those who did not (n = 29). CONCLUSIONS: In human NAFLD, no relationship between leptin levels and fibrosis stage was demonstrated. The correlation of leptin and fibrosis severity seems to be an indicator of the factors that determine leptin production.     

抵抗素与非酒精性脂肪性肝病

抵抗素是存在于血浆中的富含半胱氨酸的分泌性蛋白,属于抵抗素样分子家族,又称脂肪组织特异性分泌因子.其与胰岛素抵抗及炎症等关系密切.非酒精性脂肪性肝病(NAFLD)代表了一组以甘油三酯在肝内过度贮积而引起的临床病理综合征,目前认为其属于代谢综合征的范畴,胰岛素抵抗及炎症因子的参与是其发病的重要环节.深入研究抵抗素与胰岛素抵抗及炎症的关系将有助于进一步了解NAFLD的发病机制,为寻求合理的治疗方案提供理论依据.     

Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease

AIM To investigate the clinical, biochemical and imaging characteristics of adult cystic fibrosis(CF) patients with hepatic steatosis as compared to normal CF controls.METHODS We performed a retrospective review of adult CF patients in an academic outpatient setting during 2016. Baseline characteristics, genetic mutation analysis as well as laboratory values were collected. Abdominal imaging(ultrasound, computed tomography, magnetic resonance) was used to determine presence of hepatic steatosis. We compare patients with hepatic steatosis to normal controls.RESULTS Data was collected on 114 patients meeting inclusion criteria. Seventeen patients(14.9%) were found to have hepatic steatosis on imaging. Being overweight(BMI 25)(P = 0.019) and having a higher pp FEV1(75 vs 53, P = 0.037) were significantly associated with hepatic steatosis. Patients with hepatic steatosis had a significantly higher median alanine aminotransferase level(27 vs 19, P = 0.048). None of the hepatic steatosis patients had frank CF liver disease, cirrhosis or portal hypertension. We found no significant association with pancreatic insufficiency or CF related diabetes.CONCLUSION Hepatic steatosis appears to be a clinically and phenotypically distinct entity from CF liver disease. The lack of association with malnourishment and the significant association with higher BMI and higher pp FEV1 demonstrate similarities with non-alcoholic fatty liver disease. Long term prospective studies are needed to ascertain whether CF hepatic steatosis progresses to fibrosis and cirrhosis.     

胰岛素抵抗与非酒精性脂肪性肝病

胰岛素抵抗(IR)在非酒精性脂肪性肝病(NAFLD)发病过程中起至关重要的作用.目前大量研究支持NAFLD“二次打击”学说,初次打击IR引起肝细胞单纯性脂肪变性,二次打击脂肪变的肝细胞发生成脂性转化,诱导炎性反应、氧化应激、内质网应激的发生,损伤肝细胞功能,加重IR,促进NAFLD发展.     

强肝胶囊对非酒精性脂肪性肝病患者胰岛素抵抗指数和肝纤维化评分的影响

目的观察强肝胶囊对非酒精性脂肪性肝病(NAFLD)患者肝纤维化评分和胰岛素抵抗指数的影响。方法选取2014年8月-2015年7月在上海市第八人民医院就诊的NAFLD患者85例,随机分为治疗组(n=45)和对照组(n=40)。治疗组给予强肝胶囊,对照组给予多烯磷脂酰胆碱胶囊,2组疗程均为24周。观察2组治疗前后血清转氨酶(AST、ALT)、稳态模型胰岛素抵抗指数(HOMA-IR)以及NAFLD肝纤维化评分(NAFLDFS)的变化。计量资料组间比较采用成组t检验,组内治疗前后比较采用配对t检验;计数资料组间比较采用χ2检验。结果 2组治疗后ALT、AST水平均较同组治疗前明显改善,差异均有统计学意义(P值均0.05);与治疗前比,治疗组HOMA-IR、NAFLDFS治疗后均明显下降,差异均有统计学意义(3.58±0.85 vs 2.48±0.78,t=6.40,P0.05;-1.78±1.24 vs-2.35±0.98,t=2.40,P0.05)。2组间治疗后比较,治疗组HOMA-IR、NAFLDFS较对照组显著下降,差异均有统计学意义(2.48±0.78 vs 3.09±0.89,t=3.36,P0.01;-2.35±0.98 vs-1.48±1.08,t=3.80,P0.01)。整个疗程未见明显不良反应。结论强肝胶囊不仅能降低血清转氨酶水平,还可改善胰岛素抵抗和减轻NAFLD患者肝纤维化程度。     

非酒精性脂肪性肝病患者血清脂肪细胞因子研究进展

作为代谢综合征的肝脏表现,非酒精性脂肪性肝病（NAFLD）的主要特征为胰岛素抵抗（IR）和肝脂肪沉积。脂肪细胞因子作为脂肪细胞分泌的多肽,在 NAFLD 和 IR 的发病中发挥着重要的作用。本文综述了瘦素、脂联素、视黄醇结合蛋白4、成纤维细胞生长因子21和趋化素等新发现的细胞因子与 NAFLD 发病之间的关系。     

非酒精性脂肪性肝病进展性肝纤维化患者空腹血糖受损和胰岛素抵抗调查

目的 调查非酒精性脂肪性肝病(NAFLD)患者空腹血糖受损(IFG)和胰岛素抵抗情况及其与肝纤维化的关系。方法 2020年5月～2021年5月我院健康管理门诊诊治的NAFLD患者110例,接受口服葡萄糖耐量试验(OGTT)试验。计算稳态模型胰岛素抵抗指数(HOMA-IR),采用放射免疫法测定血清Ⅳ型胶原、Ⅲ型前胶原(PCⅢ)、层黏连蛋白(LN)和透明质酸(HA)。计算NAFLD纤维化评分(NFS),以NFS﹥0.676被定义为存在进展性肝纤维化。应用Logistic回归模型分析影响NAFLD患者发生进展性肝纤维化的因素。结果 经OGTT试验,发现本组糖耐量正常(NGT)者43例,糖耐量异常(IGT)者35例和IFG者32例;IFG组空腹血糖(FPG)、胰岛素(FINS)和HOMA-IR指数分别为(6.6±0.3)mmol/L、(10.9±2.4)μU/mL和3.2±0.9,显著高于IGT组【分别为(5.6±0.7)mmol/L、(8.5±2.2)μU/mL和2.4±0.5,P<0.05】或NGT组【分别为(5.5±0.6)mmol/L、(7.4±1.9)μU/mL和1.8±0.4...     

miRNA-103: Molecular link between insulin resistance and nonalcoholic fatty liver disease

AIM: To investigate the associations between miRNA-103(mi R-103) and insulin resistance and nonalcoholic fatty liver disease(NAFLD).METHODS: Serum samples were collected from 50 NAFLD patients who were overweight or obese(NAFLD group) and from 30 healthy subjects who served as controls(normal control group). Quantitative polymerasechain reaction was used to detect expression of mi R-103. Fasting plasma glucose, fasting insulin, and triglyceride(TG) levels were measured. Homeostasis model assessment was used to evaluate basal insulin resistance(HOMA-IR). Patient height and weight were measured to calculate body mass index(BMI).RESULTS: Compared with the normal control group, higher serum levels of mi R-103 were expressed in the NAFLD group(8.18 ± 0.73 vs 4.23 ± 0.81, P = 0.000). When P = 0.01(bilateral), mi R-103 was positively correlated with HOMA-IR(r = 0.881), TG(r = 0.774) and BMI(r = 0.878), respectively. mi R-103, TG and BMI were all independent factors for HOMAIR(β = 0.438/0.657/0.251, P = 0.000/0.007/0.001). mi R-103, TG, BMI and HOMA-IR were all risk factors for NAFLD(odds ratio = 2.411/16.196/1.574/19.11, P = 0.009/0.022/0.01/0.014).CONCLUSION: mi R-103 is involved in insulin resistance and NAFLD, and may be a molecular link between insulin resistance and NAFLD and a therapeutic target for these disorders.     

细胞因子、胰岛素抵抗与非酒精性脂肪性肝病

非酒精性脂肪性肝病(NAFLD)的发病机制目前尚不清楚,但大量研究表明胰岛素抵抗与之密切相关.随着胰岛素抵抗程度的加重,调控肝脏糖脂代谢的开关--Foxo1、Foxa2的基因活性发生不同程度的改变,导致肝脏糖脂代谢紊乱,引起NAFLD的续贯性发生.此外,与胰岛素抵抗密切相关的瘦素、肿瘤坏死因子-α作为损害性因子,脂联素作为保护性因子亦在NAFLD的发生、发展中起重要作用.